Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17607589 | 0.86 | LMNA (0.43) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL17607493 | 0.84 | LMNA (0.42) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL28794358 | 0.84 | LMNA (0.42) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL10412583 | 0.83 | ACE2 (0.38) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL28722883 | 0.83 | LMNA (0.37) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL5963220 | 0.81 | ACE2 (0.37) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL1739698 | 0.80 | MEN1 (0.33) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL4214647 | 0.79 | MEN1 (0.47) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL9490940 | 0.78 | MEN1 (0.32) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL8528821 | 0.76 | TSHR (0.42) | LMNAMEN1CYP3A4ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008028-B | Pyrimidine derivative for inhibiting growth of cancer cells and medical application thereof | 昂科比克斯有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-114746432-B | Transition metal compound, catalyst composition comprising the same, and process for producing olefin polymer using the catalyst composition | 沙特基础工业爱思开NEXLENE私人有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-10551345-B2 | Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis | APPLIED BIOSYSTEMS, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| US-20170356877-A1 | POLY AND COPOLY(N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS | APPLIED BIOSYSTEMS, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9671367-B2 | Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis | APPLIED BIOSYSTEMS, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-1814854-B1 | CATIONIC CERAMIDES, AND ANALOGS THEREOF, AND THEIR USE FOR PREVENTING OR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20140209461-A1 | Poly and Copoly(N-vinylamide)s and Their Use In Capillary Electrophoresis | APPLIED BIOSYSTEMS, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| EP-1660597-B1 | COPOLYMER SURFACTANTS | MOORE BENJAMIN & CO (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8329807-B2 | Latex paint film resistant to adverse effects of water, and compositions and methods for making same | COLUMBIA INSURANCE COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-8093393-B2 | Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2005035500-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-04-21 | — | — | WO | disclosed |
| US-6864261-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2005-03-08 | — | — | US | disclosed |
| WO-2005019353-A2 | COPOLYMER SURFACTANTS | COLUMBIA INSURANCE COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050039635-A1 | Copolymer surfactants | BENJAMIN MOORE & CO. | 2005-02-24 | — | — | US | disclosed |
| US-20050025741-A1 | Copolymers with (meth)acrylamides; improved separation of polynucleotides | APPLIED BIOSYSTEMS, LLC | 2005-02-03 | — | — | US | disclosed |
| WO-2004104054-A1 | POLY AND COPOLY (N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS | APPLERA CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040127501-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2004-07-01 | — | — | US | disclosed |
| WO-2004029044-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | EURO-CELTIQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| US-20040053914-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053914-A1 | Therapeutic agents useful for treating pain | SMN1; SMN2, OPRM1, PSEN1 | LMNA 918/4885MEN1 1955/4885CYP3A4 4358/4885 |
| US-20040127501-A1 | Therapeutic agents useful for treating pain | CACNA1A, GRIN2A, HTT | LMNA 745/4885MEN1 2295/4885CYP3A4 3931/4885 |
| US-20050025741-A1 | Copolymers with (meth)acrylamides; improved separation of polynucleotides | POLI, PCNA, POLL | LMNA 779/4885MEN1 2730/4885CYP3A4 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.